Supraspinal Neurotensin-Induced Antianalgesia in Mice Is Mediated by Spinal Cholecystokinin

• Published in: Japanese journal of pharmacology 1999, Vol.79(2), pp.141-149
• Main Authors: Holmes, Blythe B., Rady, Jodie J., Smith, David J., Fujimoto, James M.
• Format: Article
• Language: English
• Subjects: Analgesics, Opioid - antagonists & inhibitors; Animals; Anti-Anxiety Agents - pharmacology; Antianalgesia; Cholecystokinin - physiology; Cholecystokinin spinal role; Dose-Response Relationship, Drug; Drug Interactions; Hormone Antagonists - pharmacology; Immune Sera - pharmacology; Indoles - pharmacology; Injections, Intraventricular; Injections, Spinal; Male; Meglumine - analogs & derivatives; Meglumine - pharmacology; Mice; Morphine (intrathecal); Morphine - antagonists & inhibitors; Neurotensin (intracerebroventricular); Neurotensin - administration & dosage; Neurotensin - pharmacology; Proglumide - analogs & derivatives; Proglumide - pharmacology; Receptors, Cholecystokinin - antagonists & inhibitors; Spinal cholecystokinin antagonist
• ISSN: 0021-5198; 1347-3506
• DOI: 10.1254/jjp.79.141

Intracerebral injection of neurotensin into specific brain loci in rats produces hyperalgesia due to the release of cholecystokinin (CCK) in the spinal cord. The present purpose was to show in another species that neurotensin can antagonize the antinociceptive action of morphine through the spinal CCK mechanism in mice. Neurotensin given intracerebroventricularly (i.c.v.) at doses higher than 100 ng produced antinociception in the tail flick test. However, at lower doses between 1 pg to 25 ng, neurotensin antagonized the antinociceptive action of morphine given intrathecally (i.t.), thus demonstrating the antianalgesic activity of neurotensin. The rightward shift in the morphine dose-response curve produced by i.c.v. neurotensin was eliminated by an i.t. pretreatment with CCK8 antibody (5 μl of antiserum solution diluted 1:1000). I.t. administration of lorglumide, a CCKA-receptor antagonist (10–1000 ng), and PD135,158, a CCKB-receptor antagonist (250–500 ng), also eliminated the antianalgesic action of neurotensin. Thus, the mechanism of the antianalgesic action of neurotensin given i.c.v. involved spinal CCK. This mode of action is similar to that for the antianalgesic action of supraspinal pentobarbital which also involves spinal CCK.